Another PD-1 inhibitor, Nivolumab, was combined with the OV Enadenotucirev, which induced CD8+ T cell infiltration, increased Th1 cytokines, and synergistically prolonged overall survival in human CRC patients [81]. This evidence concerns the gene CD8A and colorectal carcinoma.